



Ain Shams University
Faculty of Pharmacy
Department of Pharmaceutical
Analytical Chemistry

Analytical Study of Some Drugs Used for Treating Fibromyalgia

A Thesis presented by

Eman Wafik Eskander Farag

B.SC. Pharmaceutical Sciences 2006
Faculty of Pharmacy, Ain Shams University

Presented for

the Partial Fulfillment of Master Degree in
Pharmaceutical sciences
(Pharmaceutical Analytical Chemistry)

Under the supervision of

Prof. Dr. Maha Farouk Abdel-Ghany

Professor of Pharmaceutical Analytical Chemistry &
Dean of Faculty of Pharmacy, Ain Shams University

Associate Prof. Dr. Omar Abdel Aziz

The late Associate Prof. Dr. of Pharmaceutical Analytical Chemistry
Faculty of Pharmacy, Ain Shams University

Dr. Nermine Victor Fares

Lecturer of Pharmaceutical Analytical Chemistry
Faculty of Pharmacy, Ain Shams University

(2019)

Acknowledgement

No words can ever express my sincere gratitude to "**ALLAH**" who guide, aid and bless me in every step in my life.

I am deeply grateful to **Prof. Dr. Maha Farouk Abdel-Ghany**, *Professor of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Ain Shams University*, for her valuable efforts in suggesting the point, constant advising and constructive comments.

I am greatly indebted to **Dr. Nermine Victor Fares**, *Lecturer of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Ain Shams University*, for her patience, keen interest, kind guidance, constant advice and sincere help throughout the whole study.

My deep appreciation goes to **Prof. Dr. Mohammed El Badry**, *Professor of Organic Chemistry, Faculty of Science, Ain Shams University*, for his help, guidance and general encouragement.

I would like to offer special thanks to **Associate Prof. Dr. Omar Abdel-Aziz Ali Ghonim**, *Associate Professor of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Ain Shams University*, who, although no longer with us, continues to inspire by his example and dedication, for his supervision and valuable efforts in suggesting the point.

I wish to express my heartily thanks and gratefulness to all my colleagues and managers in Amoun Pharmaceuticals Company, especially **Dr. Norma Soucre**, *Quality Department Manager*, for their keen help in carrying out my practical work.

Finally, I must express my very profound gratitude to my parents, my husband and my brother for providing me with unfailing support and continuous encouragement throughout my years of study and through the process of researching and writing this thesis. This accomplishment would not have been possible without them.

Thank you,

Eman Wafik

Table of contents	Page
List of Figures	xi
List of Tables	xix
List of Abbreviations	xxvi
Preface	xxviii
Abstract	xxx
 PART (I): Introduction and Literature Review	
I.1. Fibromyalgia	2
I.2. Medications	3
I.2.1. Pain relievers	3
I.2.2. Antidepressants	4
I.2.3. Anti-seizure drugs	6
I.3. The studied compounds	8
I.3.1. Milnacipran HCl	8
I.3.1.1. Structure	8
I.3.1.2. Properties	8
I.3.1.3. Stability of Milnacipran HCl	9
I.3.1.4. Methods of analysis of Milnacipran HCl	9
<i>I.3.1.4.1. Spectroscopic methods</i>	9
<i>1. Colorimetric methods</i>	9
<i>2. UV Spectrophotometric methods</i>	9
<i>I.3.1.4.2. Chromatographic methods</i>	10
<i>1. Gas chromatography</i>	10
<i>2. HPTLC methods</i>	10
<i>3. HPLC methods</i>	10
<i>4. Capillary electrophoresis methods</i>	15

I.3.2. Duloxetine HCl	16
I.3.2.1. Structure	16
I.3.2.2. Properties	16
I.3.2.3. Stability of Duloxetine HCl	16
I.3.2.4. Methods of analysis of Duloxetine HCl	16
<i>I.3.2.4.1. Spectroscopic methods</i>	16
1. Colorimetric methods	16
2. UV Spectrophotometric methods	16
3. Spectrofluorimetric methods	17
<i>I.3.2.4.2. Electrochemical methods</i>	17
<i>I.3.2.4.3. Chromatographic methods</i>	18
1. Gas chromatography	18
2. HPTLC methods	18
3. HPLC methods	19
I.3.3. Pregabalin	24
I.3.3.1. Structure	24
I.3.3.2. Properties	24
I.3.3.3. Stability of Pregabalin	24
I.3.3.4. Methods of analysis of Pregabalin	24
<i>I.3.3.4.1. Non-aqueous titration method</i>	23
<i>I.3.3.4.2. Spectroscopic methods</i>	25
1. Colorimetric methods	25
2. UV Spectrophotometric methods	24
3. Spectrofluorimetric methods	25
<i>I.3.3.4.3. Chromatographic methods</i>	26
1. Gas chromatography	26
2. HPTLC methods	26
3. HPLC methods	27

PART (II): High-Performance Liquid Chromatographic Methods for the Determination of Milnacipran HCl, Duloxetine HCl and Pregabalin in Presence of their Major Degradation Products

Introduction 35

Section (A): Stability-Indicating HPLC Method for Determination of Milnacipran HCl with Structure Elucidation of Degradation Products and Determination of Degradation Reaction Kinetics

II.A.1. Experimental study	38
II.A.1.1. Instrumentation	38
II.A.1.2. Samples	39
II.A.1.2.1. Pure samples	39
II.A.1.2.2. Market samples	39
II.A.1.3. Reagents	39
II.A.1.4. Stock standard solution	39
II.A.1.5. Procedure	40
II.A.1.5.1. Chromatographic conditions	40
II.A.1.5.1.1. Chromatographic conditions for HPLC/UV quantitation	40
II.A.1.5.1.2. Chromatographic conditions for LC/MS	40
II.A.1.5.2. Sample Preparation	40
II.A.1.5.3. Forced degradation of Milnacipran HCl	41
II.A.1.5.4. Method validation	44
II.A.1.5.5. Assay of Milnacipran HCl in pharmaceutical dosage forms	46
II.A.2. Results and discussion	46
II.A.2.1. Method validation	48
II.A.2.2. Application to pharmaceutical formulations	50
II.A.2.3. Degradation kinetics	50
II.A.2.4. Proposed degradation pathways	52

Section (B): Stability-Indicating HPLC Method for Determination of Duloxetine HCl with Structure Elucidation of Degradation Products and Determination of Degradation Reaction Kinetics

II.B.1. Experimental study	75
II.B.1.1. Instrumentation	75
II.B.1.2. Samples	75
II.B.1.2.1. Pure samples	75
II.B.1.2.2. Market samples	75
II.B.1.3. Reagents	75
II.B.1.4. Stock standard solution	75
II.B.1.5. Procedure	76
II.B.1.5.1. Chromatographic conditions	76
II.B.1.5.1.1. Chromatographic conditions for HPLC/UV quantitation	76
II.B.1.5.1.2. Chromatographic conditions for LC/MS	76
II.B.1.5.2. Sample Preparation	76
II.B.1.5.3. Forced degradation of Duloxetine HCl	77
II.B.1.5.4. Method validation	79
II.B.1.5.5. Assay of Duloxetine HCl in pharmaceutical dosage forms	81
II.B.2. Results and discussion	81
II.B.2.1. Method validation	83
II.B.2.2. Application to pharmaceutical formulations	84
II.B.2.3. Degradation kinetics	85
II.B.2.4. Proposed degradation pathways	86

Section (C): Stability-Indicating HPLC Method for Determination of Pregabalin with Structure Elucidation of Degradation Products and Determination of Degradation Reaction Kinetics

II.C.1. Experimental study	109
II.C.1.1. Instrumentation	109
II.C.1.2. Samples	109
II.C.1.2.1. Pure samples	109
II.C.1.2.2. Market samples	109
II.C.1.3. Reagents	109

II.C.1.4. Stock standard solution	110
II.C.1.5. Procedure	110
II.C.1.5.1. Chromatographic conditions	110
II.C.1.5.1.1. Chromatographic conditions for HPLC/UV quantitation	110
II.C.1.5.1.2. Chromatographic conditions for LC/MS	110
II.C.1.5.2. Sample Preparation	111
II.C.1.5.3. Forced degradation of Pregabalin	111
II.C.1.5.4. Method validation	113
II.C.1.5.5. Assay of Pregabalin in pharmaceutical dosage forms	115
II.C.2. Results and discussion	115
II.C.2.1. Method validation	117
II.C.2.2. Application to pharmaceutical formulations	118
II.C.2.3. Degradation kinetics	119
II.C.2.4. Proposed degradation pathways	119

PART (III): High-Performance Thin Layer Chromatographic Methods for the Determination of Milnacipran HCl, Duloxetine HCl and Pregabalin in Presence of their Major Degradation Products

Introduction 131

Section (A): Stability-Indicating HPTLC Method for Determination of Milnacipran HCl in Bulk Drug and Pharmaceutical Formulations

III.A.1. Experimental study	135
III.A.1.1. Instrumentation	135
III.A.1.2. Samples	135
III.A.1.3. Reagents	136
III.A.1.4. Standard solutions	136
III.A.1.4.1. Stock standard solution	136
III.A.1.4.2. Working solution	136
III.A.1.5. Procedure	136
III.A.1.5.1. Chromatographic conditions	136
III.A.1.5.2. Stress testing of the bulk powder	137
III.A.1.5.3. Method validation	137
III.A.1.5.4. Sample preparation	139

III.A.1.5.5. Assay of Milnacipran HCl in pharmaceutical dosage forms	139
III.A.2. Results and discussion	140
III.A.2.1. Optimization of chromatographic conditions	141
III.A.2.2. Method validation	141
III.A.2.3. Application to pharmaceutical formulations	142

Section (B): Stability-Indicating HPTLC Method for Determination of Duloxetine HCl in Bulk Drug and Pharmaceutical Formulations

III.B.1. Experimental study	153
III.B.1.1. Instrumentation	153
III.B.1.2. Samples	153
III.B.1.3. Reagents	153
III.B.1.4. Standard solution	153
III.B.1.4.1. Stock standard solution	153
III.B.1.4.2. Working solution	153
III.B.1.5. Procedure	153
III.B.1.5.1. Chromatographic conditions	153
III.B.1.5.2. Stress testing of the bulk powder	154
III.B.1.5.3. Method validation	154
III.B.1.5.4. Sample preparation	156
III.B.1.5.5. Assay of Duloxetine HCl in pharmaceutical dosage forms	156
III.B.2. Results and discussion	157
III.B.2.1. Optimization of chromatographic conditions	157
III.B.2.2. Method validation	158
III.B.2.3. Application to pharmaceutical formulations	159

Section (C): Stability-Indicating HPTLC Method for Determination of Pregabalin in Bulk Drug and Pharmaceutical Formulations

III.C.1. Experimental study	170
III.C.1.1. Instrumentation	170
III.C.1.2. Samples	170
III.C.1.3. Reagents	170
III.C.1.4. Standard solution	170
III.C.1.4.1. Stock standard solution	170

III.C.1.4.2. Working solution	170
III.C.1.5. Procedure	170
III.C.1.5.1. Chromatographic conditions	170
III.C.1.5.2. Stress testing of the bulk powder	171
III.C.1.5.3. Method validation	171
III.C.1.5.4. Sample preparation	173
III.C.1.5.5. Assay of Pregabalin in pharmaceutical dosage forms	173
III.C.2. Results and discussion	174
III.C.2.1. Optimization of chromatographic conditions	174
III.C.2.2. Method validation	175
III.C.2.3. Application to pharmaceutical formulations	176

PART (IV): Spectrophotometric Methods for the Determination of Milnacipran HCl, Duloxetine HCl and Pregabalin in Presence of their Major Degradation Products

IV.1. Introduction	184
IV.1.1. Theoretical background	184
IV.1.1.1. Dual wavelength	184
IV.1.1.2. Ratio Difference Spectrophotometric method	184
IV.1.1.3. Ratio Derivative Spectrophotometric method	185

Section (A): Stability-Indicating Spectrophotometric Methods for Determination of Milnacipran HCl in Bulk Drug and Pharmaceutical Formulations

IV.A.1. Experimental study	188
IV.A.1.1. Instrumentation	188
IV.A.1.2. Samples	188
IV.A.1.3. Reagents	188
IV.A.1.4. Standard solutions	189
IV.A.1.4.1. Stock standard solution	189
IV.A.1.4.2. Working solution	189
IV.A.1.5. Forced degradation of Milnacipran HCl	189
IV.A.1.6. Procedure	190
IV.A.1.6.1. Spectral characteristics of Milnacipran HCl and its acid and base-induced degradates	190
IV.A.1.6.2. Method validation	190

IV.A.1.6.3. Sample preparation	194
IV.A.1.6.4. Assay of Milnacipran HCl in pharmaceutical dosage forms	194
IV.A.2. Results and discussion	195
IV.A.2.1. Method validation	196
IV.A.2.2. Application to pharmaceutical formulations	198

Section (B): Stability-Indicating Spectrophotometric Methods for Determination of Duloxetine HCl in Bulk Drug and Pharmaceutical Formulations

IV.B.1. Experimental study	209
IV.B.1.1. Instrumentation	209
IV.B.1.2. Samples	209
IV.B.1.3. Reagents	209
IV.B.1.4. Standard solutions	209
IV.B.1.4.1. Stock standard solution	209
IV.B.1.4.2. Working solution	209
IV.B.1.5. Forced degradation of Duloxetine HCl	209
IV.B.1.6. Procedure	210
IV.B.1.6.1. Spectral characteristics of Duloxetine HCl and its acid-induced degradates	210
IV.B.1.6.2. Method validation	210
IV.B.1.6.3. Sample preparation	212
IV.B.1.6.4. Assay of Duloxetine HCl in pharmaceutical dosage forms	212
IV.B.2. Results and discussion	213
IV.B.2.1. Method validation	215
IV.B.2.2. Application to pharmaceutical formulations	216

Section (C): Stability-Indicating Spectrophotometric Methods for Determination of Pregabalin in Bulk Drug and Pharmaceutical Formulations

IV.C.1. Experimental study	225
IV.C.1.1. Instrumentation	225
IV.C.1.2. Samples	225
IV.C.1.3. Reagents	225
IV.C.1.4. Standard solutions	226
IV.C.1.4.1. Stock standard solution	226

IV.C.1.4.2. Working solution	226
IV.C.1.5. Forced degradation of Pregabalin	226
IV.C.1.6. Procedure	226
IV.C.1.6.1. Spectral characteristics of Pregabalin and its oxidative-induced degradates	226
IV.C.1.6.2. Method validation	227
IV.C.1.6.3. Sample preparation	229
IV.C.1.6.4. Assay of Pregabalin in pharmaceutical dosage forms	229
IV.C.2. Results and discussion	230
IV.C.2.1. Method validation	231
IV.C.2.2. Application to pharmaceutical formulations	232

PART (V): Chemometric methodsfor the Determination of Milnacipran HCl and Duloxetine HCl in Presence of their Major Degradation Products

V.1. Introduction241

V.1.1. Theoretical background241

Section (A): Determination of Milnacipran HClin Bulk Drug and Pharmaceutical Formulations in Presence of its Degradation Products by Chemometric Methods

V.A.1. Experimental study	244
V.A.1.1. Instrumentation	244
V.A.1.2. Samples	244
V.A.1.3. Reagents	244
V.A.1.4. Standard solutions	244
V.A.1.4.1. Stock standard solution	244
V.A.1.4.2. Working solution	245
V.A.1.5. Forced degradation of Milnacipran HCl	245
V.A.1.6. Procedure	245
V.A.1.6.1. Spectral characteristics of Milnacipran HCl	245
V.A.1.6.2. Experimental design of the calibration and validation sets	245
V.A.1.6.3. Sample preparation	246
V.A.1.6.4. Assay of Milnacipran HCl in pharmaceutical dosage forms	246
V.A.2. Results and discussion	247

V.A.2.1. Method validation	248
V.A.2.2. Application to pharmaceutical formulations	248

Section (B): Determination of Duloxetine HCl in Bulk Drug and Pharmaceutical Formulations in Presence of its Degradation Products by Chemometric Methods

V.B.1. Experimental study	256
V.B.1.1. Instrumentation	256
V.B.1.2. Samples	256
V.B.1.3. Reagents	256
V.B.1.4. Standard solutions	256
V.B.1.4.1. Stock standard solution	256
V.B.1.4.2. Working solution	256
V.B.1.5. Forced degradation of Duloxetine HCl	256
V.B.1.6. Procedure	257
V.B.1.6.1. Spectral characteristics of Duloxetine HCl	257
V.B.1.6.2. Experimental design of the calibration and validation sets	257
V.B.1.6.3. Sample preparation	258
V.B.1.6.4. Assay of Duloxetine HCl in pharmaceutical dosage forms	258
V.B.2. Results and discussion	258
V.B.2.1. Method validation	259
V.B.2.2. Application to pharmaceutical formulations	259

PART (VI): General Discussion

References

Arabic summary

List of Figures

Figure 1. Chemical structure of Milnacipran	8
Figure 2. Chemical structure of Duloxetine	16
Figure 3. Chemical structure of Pregabalin	24
Figure 4. HPLC chromatograms of Milnacipran HCl intact drug and its degradation products	55
Figure 5. HPLC chromatograms showing resolution between Milnacipran HCl and its degradates	56
Figure 6. Linearity curve of Milnacipran HCl intact drug (5 - 90 µg/ml)	57
Figure 7. Effect of heating on acid degradation of Milnacipran HCl versus different heating times (min.)	58
Figure 8. Effect of heating on base degradation of Milnacipran HCl versus different heating times (min.)	59
Figure 9. Effect of heating on oxidative degradation of Milnacipran HCl versus different heating times (min.)	60
Figure 10. Arrhenius plot for degradation products of Milnacipran HCl (100 µg/ml) at different heating times (minutes) versus the reciprocal of absolute temperature (Kelvin)	61
Figure 11. MS fragmentation of Milnacipran HCl intact drug	62
Figure 12. The proposed fragmentation pattern of Milnacipran HCl that ensures its LC/MS m/z values	63
Figure 13. LC/MS results of Milnacipran HCl acid-induced degradates	64
Figure 14. The proposed mechanism for acid-induced degradation of Milnacipran HCl	65

Figure 15. LC/MS results of Milnacipran HCl base-induced degradates	66
Figure 16. The proposed mechanism for base-induced degradation of Milnacipran HCl	67
Figure 17. LC/MS results of Milnacipran HCl oxidative-induced degradates	68
Figure 18. The proposed mechanism for oxidative-induced degradation of Milnacipran HCl	69
Figure 19. HPLC charts of Duloxetine HCl intact drug and its degradation products	89
Figure 20. HPLC chromatograms showing resolution between Duloxetine HCl and its degradates	90
Figure 21. Linearity curve of Duloxetine HCl intact drug (5 - 200 $\mu\text{g/ml}$)	91
Figure 22. Effect of heating on acid degradation of Duloxetine HCl versus different heating times (min.)	92
Figure 23. Effect of heating on wet-thermolysis of Duloxetine HCl versus different heating times (min.)	93
Figure 24. Arrhenius plot for degradation products of Duloxetine HCl (200 $\mu\text{g/ml}$) at different heating times (minutes) versus the reciprocal of absolute temperature (Kelvin)	94
Figure 25. MS fragmentation of Duloxetine HCl intact drug	95
Figure 26. The proposed fragmentation pattern of Duloxetine HCl that ensures its LC/MS m/z values	96
Figure 27. LC/MS results of Duloxetine HCl acid-induced degradates	97
Figure 28. The proposed mechanism for acid-induced degradation of Duloxetine HCl	98

Figure 29. LC/MS results of Duloxetine HCl wet-thermolysis degradates	99
Figure 30. The proposed mechanism for wet-thermolysis degradation of Duloxetine HCl	99
Figure 31. LC/MS results of Duloxetine HCl base-induced degradates	100
Figure 32. The proposed mechanism for base-induced degradation of Duloxetine HCl	100
Figure 33. LC/MS results of Duloxetine HCl oxidative-induced degradates	101
Figure 34. The proposed mechanism for oxidative-induced degradation of Duloxetine HCl	102
Figure 35. HPLC charts of Pregabalin intact drug and its oxidative-induced degradates	121
Figure 36. HPLC chromatogram showing resolution between Pregabalin and its oxidative-induced degradates	121
Figure 37. Linearity curve of Pregabalin intact drug (20 - 1200 µg/ml)	122
Figure 38. Effect of heating on oxidative degradation of Pregabalin versus different heating times (min.)	123
Figure 39. Arrhenius plot for oxidative degradation of Pregabalin (2 mg/ml) at different heating times (minutes) versus the reciprocal of absolute temperature (Kelvin)	124
Figure 40. MS fragmentation of Pregabalin intact drug	124
Figure 41. The proposed fragmentation pattern for Pregabalin that ensures its LC/MS m/z values	125
Figure 42. LC/MS results of Pregabalin oxidative-induced degradates	126